Hisamitsu’s Phase II Parkinson’s Patch Trials Achieves Primary Endpoint
This article was originally published in PharmAsia News
Executive Summary
Hisamitsu Pharmaceuticals’ patch-type drug HP-3000 (ropinirole) for Parkinson’s disease has achieved its primary endpoint in Phase II trials in Japan.